StockNews.com Downgrades Esperion Therapeutics (NASDAQ:ESPR) to Hold

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Monday. Several other research firms have also issued reports on ESPR. Bank of America lowered Esperion Therapeutics from a “neutral” rating to an “underperform” rating […]

Leave a Reply

Your email address will not be published.

Previous post Nature’s Sunshine Products (NASDAQ:NATR) Downgraded to “Buy” at StockNews.com
Next post StockNews.com Lowers AAON (NASDAQ:AAON) to Sell